Immunoregulatory functions of VISTA

Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525.


Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.

Keywords: VISTA; PD-1H; cancer; immunotherapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • B7 Antigens / genetics
  • B7 Antigens / immunology
  • B7 Antigens / metabolism*
  • Combined Modality Therapy
  • Genome
  • Humans
  • Immunotherapy / methods*
  • Lymphocyte Activation
  • Neoplasms / immunology
  • Neoplasms / therapy*


  • Antibodies, Monoclonal
  • B7 Antigens
  • VSIR protein, human